SCA
TEVA icon

SAC Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

SAC Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,111,200
Closed -$112M – 917
2014
Q1 		$112M Buy
2,111,200
+2,098,691
+16,777% +$97M 0.58% 28
2013
Q4 		$501K Sell
12,509
-3,409
-21% -$134K ﹤0.01% 1169
2013
Q3 		$601K Buy
15,918
+4,819
+43% +$188K ﹤0.01% 1078
2013
Q2 		$435K Buy
+11,099
New +$432K ﹤0.01% 1157

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

SAC Capital Advisors's TEVA Position: Q2 2014 in Review

SAC Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 2,111,200 shares — an estimated $112M sold.

SAC Capital Advisors first reported a position in TEVA in Q2 2013 and held it in 4 quarters. The position peaked at $112M in Q1 2014. 779 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • SAC Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,111,200 Teva Pharmaceuticals shares in Q2 2014, an estimated $112M.
  • SAC Capital Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Teva Pharmaceuticals position peaked at $112M in Q1 2014.
  • 779 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.